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characteristics of the cohort based on the presence or
absence of depression has been previously published.5
Given the lack of correlation between these variables and
depression in bivariate models, these variables were not
included in the multivariable model. In addition, the
number of events (52) limited the inclusion of too many
covariates at the risk of over-fitting the model. We agree
with Brown that perhaps one mediator between depression
and poor outcomes could be that those with depression are
more non-adherent to dietary and fluid restrictions, which
in turn leads to worse outcomes.6 Future larger studies are
warranted to address these important questions.
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To the Editor: We read with great interest the article by
Fukui M and colleagues1 evaluating the relationship between
serum bilirubin and albuminuria in patients with type II
diabetes. In this paper, the authors performed a number of
correlations and a multiple regression analysis and concluded
that the serum bilirubin level is associated with microalbu-
minuria and subclinical atherosclerosis in type II diabetic
patients.
However, these results should be interpreted with caution,
as in most of the correlations, the Pearson’s r value was below
0.2, implying a very poor correlation.2 For example, the
coefficient of determination (r2) for bilirubin pulse wave
velocity and bilirubin ankle brachial index, which are early
preclinical markers of atherosclerosis, are 0.1142¼ 0.013 and
0.1182¼ 0.0139, respectively. That is, the proportion of
variance that the variables have in common is 1.3 and
1.39%, respectively; the remaining 98.7 and 98.61% would
probably be explained by other factors, perhaps by HbA1c
levels or other parameters common and sufficiently proven to
be atherogenic in diabetic patients. The fact that these weak
correlations were statistically significant can be explained by
the large sample size of the study but does not mean that
these values are fair enough to imply any important
correlation between the examined variables. Similarly, the
adjusted R2 as well as the tolerance values in the multiple
regression model should be presented, as there seems to be a
degree of co-linearity (between age and duration of diabetes,
BMI, or systolic blood pressure) that might destabilize the
model and lead to indefinite results (for example, triglycer-
ides but not cholesterol were independent determinants of
log (urinary albumin excretion)).
In our opinion, it is quite venturesome and unwarranted
to discuss the potential preventive and therapeutic applica-
tions of bilirubin or its diagnostic utility as a new risk factor
for diabetic nephropathy and atherosclerosis based on the
current data.
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for their interest in our article,2 and the editor for the
opportunity to clarify the several points raised.
Certainly, the Pearson’s r-value between serum bilirubin
concentration and pulse wave velocity and between serum
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